971,253 Shares in Maplight Therapeutics, Inc. $MPLT Bought by Nan Fung Group Holdings Ltd

Nan Fung Group Holdings Ltd purchased a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) during the 4th quarter, Holdings Channel.com reports. The firm purchased 971,253 shares of the company’s stock, valued at approximately $17,060,000. Maplight Therapeutics accounts for about 15.3% of Nan Fung Group Holdings Ltd’s holdings, making the stock its 2nd largest position.

Several other large investors also recently bought and sold shares of the business. Strs Ohio bought a new stake in Maplight Therapeutics in the fourth quarter worth $53,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Maplight Therapeutics in the fourth quarter worth $70,000. New York State Common Retirement Fund bought a new stake in Maplight Therapeutics in the fourth quarter worth $93,000. MetLife Investment Management LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at $172,000. Finally, Walleye Capital LLC bought a new position in Maplight Therapeutics during the fourth quarter valued at $205,000.

Analysts Set New Price Targets

A number of research firms have weighed in on MPLT. TD Cowen began coverage on shares of Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating on the stock. Craig Hallum began coverage on shares of Maplight Therapeutics in a research report on Thursday, May 21st. They set a “buy” rating and a $43.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Maplight Therapeutics in a research report on Thursday, May 28th. Wall Street Zen cut shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a research report on Thursday, March 19th. They set a “buy” rating and a $35.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $37.78.

Insider Activity at Maplight Therapeutics

In other news, insider James Woodruff Lillie sold 24,811 shares of the business’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total transaction of $713,564.36. Following the completion of the sale, the insider directly owned 243,450 shares of the company’s stock, valued at approximately $7,001,622. The trade was a 9.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher A. Kroeger sold 118,235 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $27.19, for a total transaction of $3,214,809.65. Following the sale, the chief executive officer directly owned 1,394,094 shares of the company’s stock, valued at $37,905,415.86. This represents a 7.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 495,244 shares of company stock valued at $14,079,461 over the last ninety days. Company insiders own 3.80% of the company’s stock.

Maplight Therapeutics Trading Down 8.6%

Shares of MPLT opened at $27.75 on Friday. The firm has a market capitalization of $1.18 billion and a P/E ratio of -0.68. Maplight Therapeutics, Inc. has a 12-month low of $12.24 and a 12-month high of $33.28. The firm has a fifty day moving average price of $28.30 and a 200-day moving average price of $21.46.

Maplight Therapeutics (NASDAQ:MPLT) last issued its earnings results on Thursday, May 14th. The company reported ($1.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). Analysts predict that Maplight Therapeutics, Inc. will post -5.04 earnings per share for the current year.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.